Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns run through AbCellera Biologics's acquisitions — what it looks for, how it pays, and how it folds in what it buys.
2 acquisitions — each with the deal value, financing structure, target revenue, and executive commentary where disclosed.
Trianni develops genetically engineered transgenic mice for antibody discovery. Its flagship Trianni Mouse platform generates fully human monoclonal antibodies, giving AbCellera an in-house source of diverse, drug-like human antibodies to feed its microfluidic single-cell screening technology. $90.0 million initial purchase price (plus a contingent earn-out with an estimated fair value of ~$22.6 million at close).
With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies.Carl Hansen — Ph.D., CEO, AbCellera
TetraGenetics operates a proprietary platform that produces recombinant human ion channels, G protein-coupled receptors (GPCRs) and other transmembrane proteins using the protist Tetrahymena thermophila. These difficult-to-produce membrane proteins are validated but historically intractable drug targets. $12.5 million upfront cash (plus $12.5 million held in escrow) and up to $37.5 million in milestone payments; ~$48.0 million total acquisition-date consideration.
AbCellera is committed to investing in teams and technologies that have the potential to create new therapeutic opportunities, drive more value in our partnership business, and bring new therapies to patients.Carl Hansen — Ph.D., CEO, AbCellera
TetraGenetics was founded to target complex membrane proteins, many of which historically have been intractable drug targets. This acquisition recognizes our team's innovation in creating new technologies to address these therapeutically important classes of proteins.Doug Kahn — CEO, TetraGenetics